Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Rang in Aktien #26763
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Aktienkurs
$1.30
Zuletzt synchronisiert: 2023-10-13
Marktkapitalisierung
$38.02M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Zynerba Pharmaceuticals, Inc. (ZYNE)

Kategorie

Aktien-Split-Historie für Zynerba Pharmaceuticals, Inc. (ZYNE)
Die Aktie Zynerba Pharmaceuticals, Inc. (Symbol: ZYNE) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 20, 2026 statt.
Eine ZYNE-Aktie, die vor dem Aug 20, 2026 gekauft wurde, entspricht heute 0 ZYNE-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber